Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose Escalation and Expansion Study of Orca-Q, an Engineered Donor Graft Derived From Mobilized Peripheral Blood, in Recipients Undergoing Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies

NCT03802695 is registered in ClinicalTrials.gov with Orca Biosystems, Inc. as lead sponsor.

NCT NCT03802695
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03802695 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose Escalation and Expansion Study of Orca-Q, an Engineered Donor Graft Derived From Mobilized Peripheral Blood, in Recipients Undergoing Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies
Lead sponsor
Orca Biosystems, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
April 8, 2019
Completion date
December 31, 2027
Enrollment
300 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, acute myeloid leukemia, mixed phenotype acute leukemia, myelodysplastic syndromes